Zogenix, Inc. (NASDAQ: ZGNX) spotted trading -23.65% off 52-week high price. On the other end, the stock has been noted 43.31% away from the low price over the last 52-weeks. The stock changed 0.48% to recent value of $47.91. The stock transacted 492970 shares during most recent day however it has an average volume of 649.89K shares. The company has 42.33M of outstanding shares and 41.3M shares were floated in the market.
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, reported that it has completed enrollment for, and randomized the last patient into the treatment period of, Study 1601, the Company’s Phase 3 clinical trial of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine), for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), a severe and often treatment-resistant childhood-onset epilepsy.
Gail M. Farfel, Ph.D., Executive Vice President and Chief Development Officer of Zogenix said “We have been extremely pleased with the rate of enrollment in this trial and look forward to the availability of top-line safety and efficacy data in the first quarter of 2020,”. “Based on the compelling data generated in the previously completed Phase 2 study, we believe this promising drug candidate has the potential to become an important new treatment option for the control of seizures in patients suffering from LGS.”
Study 1601 is a multi-national, randomized, double-blind, placebo-controlled trial of two fixed doses of FINTEPLA as adjunctive therapy for seizures in children and adults with LGS. After establishing a baseline seizure frequency for four weeks, patients are randomized into one of three treatment groups (0.2 or 0.8 mg/kg/day FINTEPLA, maximum of 30 mg/day, or placebo) for a two-week period of dose titration before being held at a fixed dose for 12 weeks of maintenance treatment. The study randomized a total of 263 patients, with approximately 87 subjects per group. The primary endpoint of the clinical trial is the change in the number of seizures that result in drops between baseline and the combined titration and maintenance periods at the 0.8 mg/kg/day dose compared to placebo. The key secondary endpoints include change in the number of drop seizures between baseline and the combined titration and maintenance periods at the 0.2 mg/kg/day dose compared to placebo, and the proportion of patients achieving a 50% reduction in drop seizures. Patients who complete the maintenance treatment period may be eligible to enter a 12-month open-label extension to evaluate the long-term safety, tolerability and effectiveness of FINTEPLA in LGS.
FINTEPLA for the treatment of LGS has previously been designated as an orphan drug by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency.
Its earnings per share (EPS) expected to touch remained 0.90% for this year while earning per share for the next 5-years is expected to reach at 2.80%. ZGNX .
According to the most recent quarter its current ratio was 9.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of 12.06% from the mean of 20 days, 19.56% from mean of 50 days SMA and performed 10.73% from mean of 200 days price. Company’s performance for the week was -0.91%, 22.81% for month and YTD performance remained 31.40%.